title: Fatal pulmonary haemorrhage with the combined use of abciximab and fibrinolytic agent.
abstract: The increased bleeding risk associated with the use of abciximab has been well reported. The risk appears to be amplified when abciximab is administered concurrently with a fibrinolytic agent. We report and review the literature on the occurrence of a case of fatal pulmonary haemorrhage, a rare bleeding complication, in a patient who received both these drugs.
authors.affiliation: Cardiac Department, National University Hospital, 5 Lower Kent, Ridge Road, Singapore 119074. tanhc@nuh.com.sg
authors.forename: H C
authors.initials: HC
authors.lastname: Tan
authors.forename: A
authors.initials: A
authors.lastname: Low
authors.forename: K S
authors.initials: KS
authors.lastname: Ng
authors.forename: B
authors.initials: B
authors.lastname: Budiono
authors.forename: A
authors.initials: A
authors.lastname: Sutandar
authors.forename: B L
authors.initials: BL
authors.lastname: Chia
authors.forename: Y T
authors.initials: YT
authors.lastname: Lim
mesh_terms: D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D017809:Fatal Outcome; D005343:Fibrinolytic Agents / Q000009:adverse effects*; D006470:Hemorrhage / Q000139:chemically induced*; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects*; D008171:Lung Diseases / Q000139:chemically induced*; D008297:Male; D008875:Middle Aged; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D013300:Streptokinase / Q000009:adverse effects*
chemical_list: D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D013300:Streptokinase; D000077284:Abciximab